# Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer

> **NCT00920816** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 492 (actual)

## Conditions studied

- Kidney Neoplasms

## Interventions

- **DRUG:** Axitinib (AG-013736)
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT00920816
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08-25
- **Primary completion:** 2012-07-27
- **Final completion:** 2021-04-29
- **Target enrollment:** 492 (ACTUAL)
- **Last updated:** 2022-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00920816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00920816, "Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00920816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*